Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium

Key Takeaway: Spruce Biosciences announced the presentation of long-term data on Tralesinidase Alfa, an enzyme replacement therapy for Sanfilippo Syndrome Type B (MPS IIIB), at the 18th International MPS Symposium. The announcement highlights the company's ongoing commitment to addressing this rare genetic disorder. Details regarding the specific findings or implications of the data were not provided in the article.